Objectives: to assess the added value of 18 FDG-PET/CT in detection of mucinous ovarian cancer (MOC) recurrence and its effect on patient management compared to contrast enhanced computerized tomography (CECT). Methods: All patients underwent 18 F-FDG PET/CT and CECT for detection of MOC recurrence. PET/CT and CT were interpreted separately and the significance of difference between them was evaluated. Results: The study included 59 patients, out of them 18 and 29 patients were proven to have local and distant recurrence respectively. PET/CT demonstrated greater sensitivity (SN) , positive predictive value (PPV), negative predictive value (NPV) and accuracy, but the same specificity (SP) in recurrence detection (97.9%, 90.2%, 87.5%, 89.8%, and 58.3%, vs. 85.1%, 88.9%, 50%, 79.7%, and 58.3%, respectively) and showed significantly higher sensitivity for detection of omento-peritoneal and LNs metastases (mets) (36 and 27 versus 22 and 18, p- 0.0001 and 0.004, respectively). Both modalities were comparable in identifying distant organ mets (p >0.05). PET/CT changed patient management in 25.4% of patients, Conclusion: 18 FDG-PET/CT showed higher SN and accuracy than CECT in MOC recurrence detection, mainly the omento-peritoneal and nodal deposits, which allow better guidance for proper therapy planning.
No takes yet. Share an insight, caveat, or question.
Ali et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: